

ASX ANNOUNCEMENT

29 May 2023

Notice of Annual General Meeting – Withdrawal of Resolutions

BRISBANE, Australia and MINNEAPOLIS, USA, Anteris Technologies Ltd (**Anteris** or the **Company**) (ASX: AVR) advises that the Board has resolved to withdraw Resolutions 3 and 7(a)-(d) from the agenda of the Company's Annual General Meeting of shareholders scheduled to take place at 10:00 am (AEST) on Monday, 29 May 2023 (**2023 AGM**).

Resolution 3: Approval of 10% Placement Facility requested the approval of shareholders to increase the number of shares the Company is able to issue without shareholder approval over the 12-month period on and from the date of the 2023 AGM by up to 10% of the issued capital of the Company at the time of issue, under ASX Listing Rule 7.1A.

The Board has resolved to withdraw Resolution 3 because, as at the close of trading on Friday 26 May 2023, the Company is no longer an "eligible entity" within the meaning of the ASX Listing Rules on account of the Company's market capitalisation exceeding \$300 million. Therefore shareholder approval of additional placement capacity under ASX Listing Rule 7.1A is not available to the Company.

The Board has further resolved to withdraw Resolutions 7(a), 7(b), 7(c) and 7(d). These resolutions requested the approval of shareholders for the grant of Options to Mr Wayne Paterson, *Chief Executive Officer and Managing Director*, Mr John Seaberg, *Non-executive Director and Chairman*, Mr Stephen Denaro, *Non-executive Director and Company Secretary* and Mr Wenyi Gu, *Non-executive Director* respectively. Whilst the proxy support received thus far is supportive for these Resolutions, the Board wishes to review the position in light of the share price increase since when the 20 day VWAP was calculated.

The withdrawal of Resolutions 3 and 7(a)-7(d) will not affect the validity of the Proxy Form provided in connection with the 2023 AGM or any proxy votes already submitted in respect of the remaining resolutions to be put to shareholders for approval at the 2023 AGM.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga





The proven benefits of its patented ADAPT[®] tissue technology, paired with the unique design of our DurAVR[™] 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor contact

Deanne Curry
GRACosway
E: investors@anteristech.com
M: +61 414 388 997

Media contact

Nick Howe
GRACosway
nhowe@gracosway.com.au
M: +61 407 183 221

www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech
LinkedIn: <https://www.linkedin.com/company/anteristech>

For personal use only

